MannKind reported $28.14M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Adma Biologics USD 158.43M 20.76M Dec/2025
BioCryst Pharmaceuticals USD 106.82M 15.49M Dec/2025
Eli Lilly USD 21.18B 1.02B Mar/2026
Halozyme Therapeutics USD 457.99M 16.72M Mar/2026
Insmed USD 178.55M 37.7M Mar/2026
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
MacroGenics USD 13.37M 55.86M Dec/2025
MannKind USD 28.14M 10.23M Mar/2026
Merck USD 11.78B 345M Dec/2025
Novavax USD 106.45M 72.27M Dec/2025
Novo Nordisk DKK 14.27B 72.1B Jun/2025
Pfizer USD 16.17B 332M Mar/2026
Sanofi EUR 482M 85M Mar/2026
Xencor USD 12M 17.3M Mar/2026